BridgeBio Oncology Therapeutics Inc. (NASDAQ: BBOT) is a Healthcare company (Biotechnology) with a market capitalization of $156M. The Maz Rating grades it against the other companies in its sector.
BridgeBio Oncology Therapeutics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.94, BridgeBio Oncology Therapeutics Inc. trades at 0.5x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -49.0%, return on invested capital of -63.3% and a free cash flow yield of -96.3%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 4.08. Over the past 52 weeks the share price ranged from $1.93 to $14.87, with a beta of 0.39.
BridgeBio Oncology Therapeutics Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 10 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.